The estimated Net Worth of Timothy J Barberich is at least 708 千$ dollars as of 4 December 2020. Mr. Barberich owns over 50,000 units of Verastem Inc stock worth over 610,400$ and over the last 11 years he sold VSTM stock worth over 0$. In addition, he makes 97,157$ as Independent Director at Verastem Inc.
Sign up
Mr. Barberich VSTM stock SEC Form 4 insiders trading
Timothy has made over 8 trades of the Verastem Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he bought 50,000 units of VSTM stock worth 108,500$ on 4 December 2020.
The largest trade he's ever made was buying 60,538 units of Verastem Inc stock on 5 December 2017 worth over 239,125$. On average, Timothy trades about 11,657 units every 108 days since 2014. As of 4 December 2020 he still owns at least 218,000 units of Verastem Inc stock.
You can see the complete history of Mr. Barberich stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Timothy Barberich biography
Timothy Joseph Barberich is an Independent Director of the Company. Mr. Barberich is founder and former Chairman and Chief Executive Officer of Sepracor Inc., a publicly traded, research-based, pharmaceutical company based in Marlborough, Massachusetts, which was acquired by Dainippon Sumitomo Pharma Co., Ltd. in 2009. He founded Sepracor in 1984 and served as Chief Executive Officer from 1984 to May 2007 and as Chairman of the Board from 1990 to 2009. Mr. Barberich has been Chairman of BioNevia Pharmaceuticals since June 2008 and Chief Executive Officer since 2014. He currently serves on the boards of directors of publicly traded GI Dynamics,and Frequency Therapeutics, Inc., and the privately held company, TScan Biotechnology Inc. He also previously served on the boards of directors of Neurovance Inc, Inotek Pharmaceuticals, Inc., HeartWare, International, Inc., Tokai Pharmaceuticals, BioSphere Medical, Inc. and GeminX Pharmaceuticals until each company was acquired. Mr. Barberich has also served on the board of trustees of Boston Medical Center and the board of the Pharmaceutical Research and Manufacturers’ Association (PhRMA). Prior to founding Sepracor, Mr. Barberich spent 10 years as a senior executive at Bedford, Massachusetts-based Millipore Corporation. Mr. Barberich is a graduate of Kings College and holds a Bachelor’s of Science degree in Chemistry. The Board of Directors believes that Mr. Barberich’s qualifications to sit on the Board include his significant experience in the development and commercialization of pharmaceutical products, his leadership experience at other pharmaceutical companies and his service on other boards of directors.
What is the salary of Timothy Barberich?
As the Independent Director of Verastem Inc, the total compensation of Timothy Barberich at Verastem Inc is 97,157$. There are 8 executives at Verastem Inc getting paid more, with Brian Stuglik having the highest compensation of 1,917,190$.
How old is Timothy Barberich?
Timothy Barberich is 72, he's been the Independent Director of Verastem Inc since 2014. There are no older and 16 younger executives at Verastem Inc.
What's Timothy Barberich's mailing address?
Timothy's mailing address filed with the SEC is C/O FREQUENCY THERAPEUTICS, INC.,, 75 HAYDEN AVE, SUITE 300, LEXINGTON, MA, 02421.
Insiders trading at Verastem Inc
Over the last 13 years, insiders at Verastem Inc have traded over 5,883,823$ worth of Verastem Inc stock and bought 3,873,819 units worth 28,318,633$ . The most active insiders traders include Capital Management, L.P.Ra ...、Christoph H Westphal、Ansbert Gadicke. On average, Verastem Inc executives and independent directors trade stock every 28 days with the average trade being worth of 112,479$. The most recent stock trade was executed by Dan Paterson on 5 August 2024, trading 3,245 units of VSTM stock currently worth 7,009$.
What does Verastem Inc do?
verastem, inc. (nasdaq: vstm) is a biopharmaceutical company focused on discovering and developing novel drugs that selectively target cancer stem cells. cancer stem cells are an underlying cause of tumor recurrence and metastasis. verastem is translating breakthrough discoveries in cancer stem cell research into new medicines for the treatment of major cancers such as breast cancer. for more information, please visit www.versatem.com
What does Verastem Inc's logo look like?
Complete history of Mr. Barberich stock trades at Verastem Inc、Frequency Therapeutics Inc
Verastem Inc executives and stock owners
Verastem Inc executives and other stock owners filed with the SEC include:
-
Brian Stuglik,
Chief Executive Officer, Director -
Daniel Paterson,
President, Chief Operating Officer -
Robert Gagnon,
Chief Financial Officer, Chief Business Officer -
Brian M. Stuglik BPHARM, R.Ph., RPh,
CEO & Director -
Brian Stuglik R.Ph., RPh,
CEO & Director -
Daniel W. Paterson,
COO & Pres -
Robert E. Gagnon,
Chief Bus. & Financial Officer -
Michael Kauffman,
Lead Independent Director -
Timothy Barberich,
Independent Director -
Eric Rowinsky,
Independent Director -
Alison Lawton,
Independent Director -
Bruce Wendel,
Independent Director -
Gina Consylman,
Independent Director -
John Doyle,
Investor Relations -
Dr. Michelle Dipp M.D., Ph.D.,
Co-Founder -
Sean C. Flynn,
VP, Gen. Counsel & Sec. -
Erin S. Cox,
Sr. Director of Investor Relations & Corp. Communications -
Dr. Jonathan Pachter Ph.D.,
Chief Scientific Officer -
Dr. Michelle Dipp,
Co-Founder -
Dr. Piyush B. Gupta Ph.D.,
Co-Founder -
Dr. Robert A. Weinberg,
nder & Former Chair of Scientific Advisory Board -
Richard H. Aldrich M.B.A., Mba,
Founder and Consultant -
S. Louise Phanstiel,
Director -
Joseph Chiapponi,
Vice President of Finance -
John B Green,
Chief Financial Officer -
Monica Singh,
General Counsel -
Henri A Termeer,
Director -
Stephen A Sherwin,
Director -
Christoph H Westphal,
Executive Chairman -
Paul A Friedman,
Director -
Karin Anna Tollefson,
Director -
Steven H. Bloom,
Chief Strategy Officer -
Julie B Feder,
Chief Financial Officer -
Robert Forrester,
President and CEO -
Ngoc Diep T. Md, Ph D Le,
Chief Medical Officer -
Joseph M Lobacki,
Executive VP & CCO -
Gregory Berk,
Chief Medical Officer -
Capital Investments L.P.Rid...,
-
Capital Management, L.P.Ra ...,
-
John Johnson,
Director -
Management Co. Llc Deer,
Director -
Iii Lp Chp,
10% owner -
John K Clarke,
Director -
Joanna Horobin,
Chief Medical Officer -
Jonathan Pachter,
VP, Head of Research -
Fund, L.P. Longwood,
10% owner -
Venture Partners Vii L.P.Be...,
-
Stephen Kraus,
Director -
Ansbert Gadicke,
Director -
Bioventures V Llcmpm Bioven...,
-
Piyush Gupta,
10% owner -
Iii Lpchp Iii Management, L...,
-
Daniel Calkins,
Chief Financial Officer -
Frank Neumann,
Chief Medical Officer -
Paul A. Bunn,
Director -
Lesley Kim Solomon,
Director -
Michelle Robertson,
Director -
Anil Kapur,
Director -
Dan Paterson,
President and CEO